Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
IPO Year: 2014
Exchange: NASDAQ
Website: caratherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/13/2024 | $6.00 → $1.00 | Buy → Hold | Stifel |
| 6/13/2024 | $10.00 → $1.00 | Buy → Hold | Canaccord Genuity |
| 6/13/2024 | Buy → Hold | Needham | |
| 6/13/2024 | Buy → Neutral | H.C. Wainwright | |
| 3/8/2023 | $13.00 → $6.00 | Neutral → Underperform | BofA Securities |
| 3/8/2022 | $17.00 → $20.00 | Neutral → Overweight | JP Morgan |
| 11/1/2021 | $33.00 | Buy | Canaccord Genuity |
| 8/24/2021 | $33.00 → $35.00 | Buy | HC Wainwright & Co. |
| 8/3/2021 | $16.00 | Neutral | JP Morgan |
GAINERS: Global Hemp Group (OTC:GBHPF) shares closed up 117.39% at $0.04 CordovaCann (OTC:LVRLF) shares closed up 19.90% at $0.06 SOL Glb Inv (OTC:SOLCF) shares closed up 19.40% at $0.06 1933 Industries (OTC:TGIFF) shares closed up 11.81% at $0.01 Global Compliance (OTC:FUAPF) shares closed up 10.37% at $0.00 CLS Holdings USA (OTC:CLSH) shares closed up 6.01% at $0.04 22nd Century Group (NASDAQ:XXII) shares closed up 4.77% at $0.72 EnWave (OTC:NWVCF) shares closed up 4.53% at $0.17 Psychemedics (NASDAQ:PMD) shares closed up 3.52% at $2.24 cbdMD (AMEX:YCBD) shares closed up 3.11% at $0.63 LOSERS: Green Growth Brands (OTC:GGBXF) shares closed down 99.00% at $1e-06 Leafbuyer Techs (OTC:LBUY)
GAINERS: Pharmadrug (OTC:LMLLF) shares closed up 85.78% at $0.01 Heritage Cannabis Holding (OTC:HERTF) shares closed up 66.67% at $0.001 Cann Gr (OTC:CNGGF) shares closed up 37.93% at $0.02 4Front Ventures (OTC:FFNTF) shares closed up 27.16% at $0.10 Elixinol Wellness (OTC:ELLXF) shares closed up 25.00% at $0.00 Kaya Holdings (OTC:KAYS) shares closed up 22.97% at $0.04 CNBX Pharmaceuticals (OTC:CNBX) shares closed up 17.19% at $0.01 Body and Mind (OTC:BMMJ) shares closed up 12.02% at $0.03 Cansortium (OTC:CNTMF) shares closed up 10.62% at $0.12 Cara Therapeutics (NASDAQ:CARA) shares closed up 10.45% at $0.37 Auxly Cannabis Group (OTC:CBWTF) shares closed up 8.56% at $0.03 Scotts Miracle Gro
GAINERS: Australis Capital (OTC:AUSAF) shares closed up 9900.00% at $0.01 Global Hemp Group (OTC:GBHPF) shares closed up 70.36% at $0.05 Maple Leaf Green World (OTC:MGWFF) shares closed up 68.48% at $0.05 CordovaCann (OTC:LVRLF) shares closed up 42.50% at $0.06 Target Group (OTC:CBDY) shares closed up 25.00% at $0.00 Blueberries Medical (OTC:BBRRF) shares closed up 19.09% at $0.01 CLS Holdings USA (OTC:CLSH) shares closed up 17.00% at $0.04 Zelira Therapeutics (OTC:ZLDAF) shares closed up 15.32% at $0.55 Leafbuyer Techs (OTC:LBUY) shares closed up 14.67% at $0.02 Canopy Gwth (NASDAQ:CGC) shares closed up 10.92% at $7.14 SOL Glb Inv (OTC:SOLCF) shares closed up 10.66% at $0.05 Cansortium (OT
GAINERS: Zelira Therapeutics (OTC:ZLDAF) shares closed up 69.95% at $0.48 Global Hemp Group (OTC:GBHPF) shares closed up 40.00% at $0.03 CordovaCann (OTC:LVRLF) shares closed up 29.03% at $0.04 Elixinol Wellness (OTC:ELLXF) shares closed up 25.00% at $0.00 Eastside Distilling (NASDAQ:EAST) shares closed up 23.57% at $1.20 Body and Mind (OTC:BMMJ) shares closed up 15.70% at $0.04 Pharmadrug (OTC:LMLLF) shares closed up 15.25% at $0.01 1933 Industries (OTC:TGIFF) shares closed up 14.86% at $0.01 Maple Leaf Green World (OTC:MGWFF) shares closed up 10.69% at $0.03 Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 10.42% at $58.92 Rocky Mountain High (OTC:RMHB) shares closed up 8.33% at $0.0
GAINERS: Australis Capital (OTC:AUSAF) shares closed up 9900.00% at $0.0001 Cara Therapeutics (NASDAQ:CARA) shares closed up 25.84% at $0.37 4Front Ventures (OTC:FFNTF) shares closed up 23.42% at $0.10 Cannabix Technologies (OTC:BLOZF) shares closed up 15.92% at $0.43 Global Compliance (OTC:FUAPF) shares closed up 12.75% at $0.01 22nd Century Group (NASDAQ:XXII) shares closed up 11.92% at $0.79 Curaleaf Holdings (OTC:CURLF) shares closed up 9.71% at $4.18 SOL Glb Inv (OTC:SOLCF) shares closed up 9.05% at $0.04 OrganiGram Holdings (NASDAQ:OGI) shares closed up 7.59% at $1.70 RIV Capital (OTC:CNPOF) shares closed up 7.14% at $0.10 GrowGeneration (NASDAQ:GRWG) shares closed up 6.82% at $2.35 A
Cara Therapeutics Inc (NASDAQ:CARA) shares are trading higher by 11.5% to 32 cents during Thursday’s session. The company earlier announced it engaged Piper Sandler & Co. as a financial advisor to explore strategic alternatives to enhance shareholder value. CEO Christopher Posner stated that the company aims to evaluate various options while implementing a cost-containment and cash conservation plan. There is no guarantee that this process will lead to any agreements or transactions, and further updates will only be provided if the Board approves a specific action or if legally required. As of March 31, Cara Therapeutics said the company had about $70 million in cash and marketable se
As of March 31, 2024, the Company had approximately $70 million in cash, cash equivalents, and marketable securities.
GAINERS: MJ Holdings (OTC:MJNE) shares closed up 44.44% at $0.00 CLS Holdings USA (OTC:CLSH) shares closed up 15.83% at $0.05 Maple Leaf Green World (OTC:MGWFF) shares closed up 11.28% at $0.03 Rocky Mountain High (OTC:RMHB) shares closed up 8.27% at $0.01 Charlottes Web Holdings (OTC:CWBHF) shares closed up 5.92% at $0.17 Greenlane Hldgs (NASDAQ:GNLN) shares closed up 5.88% at $0.26 Zoned Props (OTC:ZDPY) shares closed up 5.28% at $0.66 22nd Century Group (NASDAQ:XXII) shares closed up 4.09% at $0.71 Aurora Cannabis (NASDAQ:ACB) shares closed up 3.74% at $5.69 EnWave (OTC:NWVCF) shares closed up 3.57% at $0.17 Tilray Brands (NASDAQ:TLRY) shares closed up 3.41% at $1.83 Cara Therapeutics (N
GAINERS: MJ Holdings (OTC:MJNE) shares closed up 36.54% at $0.00 Kaya Holdings (OTC:KAYS) shares closed up 22.37% at $0.05 Maple Leaf Green World (OTC:MGWFF) shares closed up 11.47% at $0.03 Charlottes Web Holdings (OTC:CWBHF) shares closed up 11.19% at $0.18 Nextleaf Solutions (OTC:OILFF) shares closed up 6.91% at $0.07 Cara Therapeutics (NASDAQ:CARA) shares closed up 6.51% at $0.28 Eastside Distilling (NASDAQ:EAST) shares closed up 4.21% at $1.00 Mexco Energy (AMEX:MXC) shares closed up 3.51% at $11.86 LOSERS: Khiron Life Sciences (OTC:KHRNF) shares closed down 99.00% at $1e-06 The Flowr (OTC:FLWPF) shares closed down 99.00% at $1e-06 Affinor Growers (OTC:RSSFF) shares closed down 45.18
GAINERS: GreenGro Technologies (OTC:GRNH) shares closed up 900.00% at $1e-05 CordovaCann (OTC:LVRLF) shares closed up 50.89% at $0.07 1933 Industries (OTC:TGIFF) shares closed up 47.06% at $0.01 Kaya Holdings (OTC:KAYS) shares closed up 29.70% at $0.04 Target Group (OTC:CBDY) shares closed up 24.28% at $0.00 Global Compliance (OTC:FUAPF) shares closed up 23.20% at $0.01 MJ Holdings (OTC:MJNE) shares closed up 22.41% at $0.00 CV Sciences (OTC:CVSI) shares closed up 19.77% at $0.06 Pharmadrug (OTC:LMLLF) shares closed up 11.11% at $0.01 4Front Ventures (OTC:FFNTF) shares closed up 10.95% at $0.07 Eastside Distilling (NASDAQ:EAST) shares closed up 7.29% at $0.97 Genetic Technologies (NASDAQ:GE
STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Helen M. Boudreau to its Board of Directors. Ms. Boudreau has more than 30 years of operating experience in a variety of industries, including the biotechnology and pharmaceutical sectors, in addition to serving as a director on numerous public boards. "We are pleased to welcome Helen to the Cara board," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "We look forward to leveraging her
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company's Board of Directors. Mr. Posner is currently the president and CEO of Cara Therapeutics (NASDAQ:CARA), a commercial-stage biopharmaceutical company.
STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors. Dr. von Moltke currently serves as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc. "We are very pleased to welcome Lisa to our board of directors," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "Her extensive clinical development and pharmacology expertise will be of great value as we continue executing o
STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position
STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Christopher Posner, a current member of the Company's Board of Directors, has been appointed President and Chief Executive Officer, effective November 9, 2021. Mr. Posner succeeds Dr. Derek Chalmers, who will transition to a Senior Advisor role. Mr. Posner joins the Company from LEO Pharma, Inc., the US affiliate of LEO Pharma A/S, a global leader in medical dermatology, where he was President and CE
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced the appointment of Mani Mohindru, PhD to the Company’s board of directors. Dr. Mohindru brings to CytomX deep and varied experience across the life sciences industry, with particular experience in finance and corporate strategy. “We are pleased to welcome Mani to CytomX’s board of directors,” commented Sean McCarthy, D.Phil., president, chief executive officer (CEO) and chairman of CytomX. “Mani brings a
SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies without the need for human serum, today announced the appointment of Mani Mohindru, PhD, and Mervyn Turner, PhD to its Board of Directors. “We are excited to welcome Drs. Mohindru and Turner to our Board of Directors. Each industry executive brings a wealth of corporate strategy, drug development and financial expertise,” said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics. “Both Drs. Mohindru and Turner are joining SAB at a p
4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity
STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced that it has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and reviewing strategic alternatives. "We are committed to evaluating a range of strategic options to maximize value for our shareholders," said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. "As part of this effort, our Board of Directors has approved a streamlined operating plan focused on cost-containment and cash conservation." There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica (NP). Oral difelikefalin did not demonstrate a meaningful clinical benefit at
STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2024. "Our notalgia paresthetica (NP) pivotal clinical program is progressing ahead of schedule and we now expect to report topline efficacy and safety results from KOURAGE 1 Part A by the end of the second quarter of 2024," said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. "We believe the medical dermatology community's intere
STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close. The press release will be available under "Press Releases" in the Investors section of the Company's website at www.CaraTherapeutics.com. About Cara Therapeutics Cara Therapeutics is a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company is dev
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT. A webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days. About Cara Therapeutic
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual key opinion leader (KOL) event titled "Meet the NP Experts" on Wednesday, March 27, 2024, at 10:00 a.m. EDT. The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemiology, diagnosis, treatment landscape, and significant unmet medical need in notalgia paresthetica (NP). The live panel discussion will be moderated by Joana Goncalves, MD, Chief Medical Officer of Cara Th
–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operatio
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com. About Cara Therapeutics Cara Therapeutics is a commercial-stage biopharmaceutical co
– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce reduction of up to 50% – – Cara ended 2023 with approximately $101 million in cash; runway extended into 2026 – – Company to host conference call and webcast today at 8:30 a.m. EST – STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the
– Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruritus associated with atopic dermatitis – – Late-stage oral difelikefalin clinical programs for pruritus associated with notalgia paresthetica and advanced chronic kidney disease continue to enroll on track with key data readouts expected in 2H24 – – Cara expects to end 2023 with approximately $100 million in cash – STAMFORD, Conn., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve
Stifel downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $6.00 previously
Canaccord Genuity downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $10.00 previously
Needham downgraded Cara Therapeutics from Buy to Hold
H.C. Wainwright downgraded Cara Therapeutics from Buy to Neutral
BofA Securities downgraded Cara Therapeutics from Neutral to Underperform and set a new price target of $6.00 from $13.00 previously
JP Morgan upgraded Cara Therapeutics from Neutral to Overweight and set a new price target of $20.00 from $17.00 previously
Canaccord Genuity resumed coverage of Cara Therapeutics with a rating of Buy and set a new price target of $33.00
HC Wainwright & Co. reiterated coverage of Cara Therapeutics with a rating of Buy and set a new price target of $35.00 from $33.00 previously
JP Morgan initiated coverage of Cara Therapeutics with a rating of Neutral and set a new price target of $16.00
Needham reiterated coverage of Cara Therapeutics with a rating of Buy and set a new price target of $26.00 from $35.00 previously
–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operatio
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com. About Cara Therapeutics Cara Therapeutics is a commercial-stage biopharmaceutical co
– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce reduction of up to 50% – – Cara ended 2023 with approximately $101 million in cash; runway extended into 2026 – – Company to host conference call and webcast today at 8:30 a.m. EST – STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the
– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all three late-stage oral difelikefalin clinical programs anticipated within current financial runway – – Topline results from Part A of KIND 1 Phase 3 atopic dermatitis trial expected in December 2023 – – 3Q23 total revenue of $4.9M including collaborative revenue of $1.9M from the Company's share of profit of KORSUVA® (difelikefalin) injection – – Conference call today at 4:30 p.m. EST – STAMFORD, Conn., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new t
STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, November 13, 2023, at 4:30 p.m. ET to report third quarter 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company'
– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company's share of profit of KORSUVA® (difelikefalin) injection – – Demand for KORSUVA injection accelerating with 46% increase in vial orders quarter to quarter – – 2024 ESRD PPS proposed rule suggests additional funding for TDAPA-designated products in existing functional category; final rule expected in 4Q23 – – Three late-stage oral difelikefalin clinical programs tracking to plan; Internal readout of Part A of KIND 1 atopic dermatitis trial expected in 4Q23 – – Conference call today at 4:30 p.m. EDT – STAMFORD, Conn., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercia
STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, August 7, 2023, at 4:30 p.m. ET to report second quarter 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company's
– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company's share of profit of KORSUVA® (difelikefalin) injection – – Acceleration in demand for KORSUVA injection as evidenced by total vial sales more than doubling quarter to quarter – – Three late-stage oral difelikefalin clinical programs progressing with internal readout of Part A of KIND 1 AD trial on track for 4Q23 – – Conference call today at 4:30 p.m. EDT – STAMFORD, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announc
STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to report first quarter 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the News & Investors section of the Company
– 4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Company's share of profit of KORSUVA® (difelikefalin) injection; FY22 revenue was $41.9 million including collaborative revenue of $16.6 million – – Positive momentum across first four EU launches; Global rollout to accelerate with most EU countries launching in 2023 – – Phase 2/3 clinical program of oral difelikefalin in NP initiated in 2023; NDD CKD and AD programs tracking to expectations with internal readout from KIND 1 Part A expected in 2H23 – – Conference call today at 4:30 p.m. EST – STAMFORD, Conn., March 06, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a
10-Q - Cara Therapeutics, Inc. (0001346830) (Filer)
10-Q - Cara Therapeutics, Inc. (0001346830) (Filer)
8-K - Cara Therapeutics, Inc. (0001346830) (Filer)
8-K - Cara Therapeutics, Inc. (0001346830) (Filer)
8-K - Cara Therapeutics, Inc. (0001346830) (Filer)
424B5 - Cara Therapeutics, Inc. (0001346830) (Filer)
8-K - Cara Therapeutics, Inc. (0001346830) (Filer)
10-Q - Cara Therapeutics, Inc. (0001346830) (Filer)
8-K - Cara Therapeutics, Inc. (0001346830) (Filer)
DEFA14A - Cara Therapeutics, Inc. (0001346830) (Filer)
SC 13D - Cara Therapeutics, Inc. (0001346830) (Subject)
SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)
SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)
SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)
SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)
SC 13G - Cara Therapeutics, Inc. (0001346830) (Subject)
SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)
SC 13G - Cara Therapeutics, Inc. (0001346830) (Subject)
SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)
SC 13G - Cara Therapeutics, Inc. (0001346830) (Subject)